BioSpace News Archive

On Sunday, October 7, Apple demonstrated its Apple Watch heath based capabilities by featuring “Calor”, a new app aimed at protecting rural farm workers toiling in summer fields picking the nation’s fruits and vegetables.

Long-term oxygen therapy does not decrease the risk for hospitalizations or increase life expectancy for many patients with mild to moderate COPD, but may lower their quality of life, according to Mayo Clinic researchers published in The Journal of the American Osteopathic Association.

Interrad Medical, a privately held medical device company, announces an agreement with Vygon to distribute the SecurAcath Subcutaneous Catheter Securement Device in France.

Sidley Austin LLP announced today that Tom Duley has joined the firm as a partner in its global Life Sciences practice.

Tivic Health Systems Inc. (Tivic HealthTM), a bioelectronic health-tech company, announced their first bioelectronic product, ClearUP™ Sinus Pain Relief (ClearUP™

MADISON, Wis., /PRNewswire/ -- New research from Propeller Health, a leading digital therapeutics company, suggests that clinical guidelines for assessing asthma control may need to be updated to reflect objective patient information obtained from digital medicines.

Acacia Pharma Group plc (“Acacia Pharma”), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for BARHEMSYS(TM) (amisulpride injection).

MedMen Enterprises Inc. (“MedMen” or the “Company”) (CSE: MMEN) (OTCQB: MMNFF) (FSE: A2JM6MN) opened MedMen Paradise over the weekend, its second branded store in Las Vegas.

This week Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and a global leader in healthcare communications, welcomed more than 150 attendees to Connect 18, the Company’s annual conference for healthcare professionals.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from its OASIS Phase 2 clinical study for its investigational drug candidate etrasimod, a next-generation, oral, S1P receptor modulator with optimized activity being evaluated in ulcerative colitis (UC), were presented by Dr. William J. Sandborn at the American College of Gastroenterology Annual Meeting.